Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein … (NCT06242405) | Clinical Trial Compass
CompletedNot Applicable
Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
China92 participantsStarted 2024-03-05
Plain-language summary
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Randomized controlled trials have confirmed the efficacy of single infusion of stem cells in treating ESLD. It seems that the multiple infusion is better than single infusion.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. 18-80 years old
* 2\. End-stage liver disease
* 3\. Signed informed consent
Exclusion Criteria:
* 1\. Tumours of the liver or other organs
* 2\. Liver transplantation recipients
* 3\. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
* 4\. Other diseases that may seriously affect the survival
* 5\. Human immunodeficiency syndrome
* 6\. Interferon or glucocorticoid therapy within 1 year
* 7\. Treated for mental illness
* 8\. Participation in other clinical trials within 30 days
* 9\. Pregnant or breastfeeding subjects
* 10\. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
* 11\. Other circumstances that are unsuitable for participation in this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Proportion of patients with Child A
Timeframe: 24 weeks
Trial details
NCT IDNCT06242405
SponsorGeneral Hospital of Shenyang Military Region